{"classes":[{"categories":[{"measurements":[{"comment":"The number of responders is not enough to estimate a standard error for the confidence interval.","groupId":"OG000","lowerLimit":"2.05","upperLimit":"NA","value":"17.36"}]}],"title":"mRECIST"},{"categories":[{"measurements":[{"comment":"The number of responders is not enough to estimate a standard error for the confidence interval.","groupId":"OG000","lowerLimit":"0.73","upperLimit":"NA","value":"4.20"}]}],"title":"RECIST"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Defined as the time from the start of combination therapy until the earliest date of disease progression or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"INCAGN01876 in combination with pembrolizumab and epacadostat","id":"OG000","title":"INCAGN01876 + Pembrolizumab + Epacadostat"}],"paramType":"MEDIAN","populationDescription":"The FAS includes all participants enrolled in the study who received at least 1 dose of INCAGN01876, pembrolizumab, or epacadostat.","reportingStatus":"POSTED","timeFrame":"Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months","title":"Phase 1 & Phase 2: Progression-free Survival Based on RECIST v1.1 and mRECIST","type":"SECONDARY","unitOfMeasure":"months"}